Figure 4
Oxo effect on ROS levels and on SOD1 and SOD2 protein levels and activity in the hippocampus. Cropped band-images of representative Western blot results. (A) The analysis of global ROS levels following acute Oxo treatment revealed a significant decrease in all the studied time points (24 h, 48 h and 72 h) as compared to control group (Ctrl). (B) The selective analysis of 1O2 species levels following acute Oxo treatment revealed a significant decrease in all the studied time points (24 h, 48 h and 72 h) as compared to control group (Ctrl). The scopolamine (Scop), injected 20 min before of acute Oxo treatment, completely blocked Oxo effect on global ROS and 1O2 species levels. Scopolamine alone did not show significant changes of both global ROS and 1O2 species levels. (C,D) The analysis of SOD1and SOD2 protein levels at different time-points (24 h, 48 h and 72 h) revealed a significant increase only for SOD2 at 72 h as compared to control group. Scopolamine pretreatment completely blocked the increase of SOD2 protein levels. The group treated with scopolamine alone did not show significant change of SOD1 and SOD2 protein levels. (E) The analysis of SOD activity evidenced a significant increase of SOD activity at 48 h and 72 h after acute Oxo treatment as compared to control group. Scopolamine pretreatment completely blocked Oxo effect on SOD activity. Scopolamine alone did not show significant changes of SOD activity as compared to control group. Full-length band-lines are presented in Supplementary Fig. S2. Data are reported as means ± SE. PLSD: **P < 0.01, ***P < 0.001, ****P < 0.0001.
